The general practitioner considers hypertension to be a symptomless condition until it has done some damage to medium-sized arteries, when there are problems of cerebrovascular deficit, coronary artery disease and renal failure. Patients are not well motivated to present for treatment and they will not accept control of a condition which is symptomless, until it is too late. Doctors, on the other hand, are not motivated to continue treatment when side effects are brought on by treatment. With the appearance of beta blockers in general and atenolol (Tenormin) in particular, aggressive detection of hypertension was encouraged. The benefits of such action are a fall in mortality, morbidity, the incidence of cerebrovascular disease and, to a lesser extent, complicating coronary artery disease. All of these have important economic implications.
The treatment of hypertension has involved multi-drug regimes because the early drugs, including the first beta blockers, have caused dose-limiting side effects. Increasing the dose caused increasing side effects, and drugs given in sub-side-effect doses were often ineffective. The addition of second, third and fourth drugs produced further hypotensive effects.
An early drug, veratrum viride, a plant alkaloid, was studied in the 1950s in an attempt to isolate the active compound, described by Osgood in 1835 as a 'poison causing bradycardia, vomiting and hypotension'. Ganglion blockers gave some encouragement in the 1950s but could only be used in malignant hypertension, while rauwolfia and central amine depleters caused quite serious trouble to patients. Thiazides then appeared together with peripheral vasodilators such as hydrallazine. Hydrallazine is still in use, but it causes headache in 75 % of cases and GPs find that this is a reason for it to be withdrawn from the regime. There are problems with hypotensive drugs, both for patients and doctors. For doctors there is the delay in onset of effect, a dose increment with lowered effects, often a very wide dose range, and tricky or dangerous drug interaction. In any general practice there are a significant number of poorly controlled hypertensives who are on conventional therapy. Thus twelve general practitioners, when asked, were quickly able to identify 73 such subjects.
Being reluctant to change entirely to a new agent, these doctors preferred to add therapy, with the proviso that the added agent must control hypertension in its own right, must be compatible with existing drugs in the regime, and must not add to the frequency of dosage. Further, it must have no further imposition on the patient, and no side effects of its own. Among the drugs which are already in use, methyldopa is the most widely used and in the present trial the drug added was atenolol, the new beta blocker, which is an effective antihypertensive (Myers et al. 1976) in a single daily dose of 100 mg without a complicated run-in period (Douglas-Jones & Cruickshank 1976 ). The incidence of side effects has been shown to be equivalent to that of placebo (Petrie et al. 1975 , Hansson et al. 1975 ).
Trial Design
The objectives of the present trial were to show that the addition of atenolol to any current regime gave better control of blood pressure and had an acceptable level of side effects. The trial was multicentred among selected general practitioners and the patients were known hypertensives who were on existing treatment. They were aged between 18 and 70, with diastolic pressures between 100 and 120 mmHg; the readings were taken after five minutes sitting quietly at rest. Patients were excluded who were (1) already on beta blockers, (2) were pregnant, or wished to become pregnant, (3) had myocardial ischaemia, (4) had congestive heart failure, (5) bronchospasm, or (6) a raised blood urea. It was a double-blind crossover trial of 100 mg of atenolol against placebo. Existing therapy was continued throughout the trial period of 16 weeks and the change in regime was made at four-weekly intervals (Fig 1) . At entry and at each four-week assessment measurement of the resting blood pressure was made after the patient had been sitting for five minutes. The pulse rate and body weight were measured, and blood and urine tests were carried out. A side effect questionnaire was completed by the doctor and patient. Eight patients were incorrectly recruited, there were incomplete data for another 8, and there were 6 withdrawals, making a total of 22 not available for analysis. Fifty-one patients remained to be analysed. The patients in this study were already taking a multitude of antihypertensive agents, but the other beta blockers were excluded (Table 1) .
Results
The mean pressures at entry were 180/107 mmHg, and while there was a noticeable placebo effect after one month, the effect of a daily dose of 100 mg of atenolol was statistically significant (Fig 2) . Placebo had no effect on pulse rate but atenolol showed the expected beta-blocking effect (Fig 3) .
Seventy-six per cent of subjects had no additional side effects on atenolol over and above those admitted initially, and some subjects volunteered that they felt much better. shows the side effects divided into the five original categories. These were not statistically greater than placebo and no side effects were serious or intrusive. Withdrawals on atenolol were attributed to sinus headaches and vertigo; one patient had depression and probably should not have been recruited, while one presented with an aortic aneurysm and promptly withdrew from the trial. Placebo withdrawals included one from lack of effect and 2 with giddiness, blurred vision and dyspepsia. The other tests of body weight, blood urea, sodium, potassium, chloride and urine sugar showed no change throughout the trial. After eight weeks the control of blood pressure in 50 subjects was well maintained, the pulse rate was lower and no abnormalities had been detected.
Conclusion
Atenolol is effective in a single daily dose in a group of patients who are difficult to control, and this is not only highly significant, but clinically it is a highly acceptable finding. There was a remarkably low incidence of minor side effects, which were only slightly above placebo level. This could possibly be due to the fact that these patients were on a multi-drug therapy. It is therefore concluded that, where inadequately controlled hypertensives are under consideration, the addition of 100 mg of atenolol once a day is a logical next step.
